In vivo and in vitro bioequivalence testing

Journal of Bioequivalence and Bioavailability

Volumn 6, Issue 2, 2014, Pages 67-74

  Lu, Ying ^a   Chow, Shein Chung ^b,c   Zhu, Shichen ^c,d  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CIVIL AVIATION UNIVERSITY OF CHINA   (China)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Fundamental bioequivalence assumption; Highly variable drugs; In vitro in vivo correlation; Individual bioequivalence; Population bioequivalence

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BOOTSTRAPPING; CLINICAL ASSESSMENT; DRUG ABSORPTION; GEOMETRY; MAXIMUM PLASMA CONCENTRATION; PARTICLE SIZE; PHARMACODYNAMICS; PRESCRIPTION;

EID: 84899425643     PISSN: None     EISSN: 09750851     Source Type: Journal    
DOI: 10.4172/jbb.1000182     Document Type: Article

References (20)

1. FDA (1999) Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products-Center for Drug Evaluation and Research, the US Food and Drug Administration, Rockville, Maryland, USA.
2. FDA (2003) Guidance on Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products-General Considerations, Center for Drug Evaluation and Research, the US Food and Drug Administration, Rockville, Maryland, USA.
3. Chow SC, Liu JP (2008) Design and Analysis of Bioavailability and Bioequivalence Studies. (3rdedn), Chapman Hall/CRC Press, Taylor & Francis, New York, New York, USA.
4. Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657-680.
5. Westlake WJ (1976) Symmetrical confidence intervals for bioequivalence trials. Biometrics 32: 741-744.
6. Fieller EC (1954) Some problems in interval estimation. Journal of the Royal Statistical Society, Series B 16: 175-185.
7. Chow SC, Shao J, Wang H (2002) Individual bioequivalence testing under 2x3 designs. Stat Med 21: 629-648.
8. Wilcoxon F (1945) Individual comparisons by ranking methods. Biometrics Bulletin, 1: 80-83.
9. Hodges JL, Lehmann EL (1963) Estimation of location based on ranks. Annals of Mathematical Statistics, 34: 598-611.
10. FDA (2010) Biologics Price Competition and Innovation Act, Center for Drug Evaluation and Research, the US Food and Drug Administration, Rockville, Maryland, USA.
11. FDA (2012) Scientific considerations in demonstrating biosimilarity to a reference product. The United States Food and Drug Administration, Silver Spring, Maryland, USA.
12. Wang H, Zhang Y, Shao J, Chow SC (2000) In vitro bioequivalence testing. In Encyclopedia of Biopharmaceutical Statistics, Ed. Chow, S.C., 2nd edition, Marcel Dekker, Inc., New York, New York.
13. Chow SC, Shao J, Wang H (2003) In vitro bioequivalence testing. Stat Med 22: 55-68.
14. Hyslop T, Hsuan F, Holder DJ (2000) A small sample confidence interval approach to assess individual bioequivalence. Stat Med 19: 2885-2897.
15. HC (2006) The Safety and Effectiveness of Generic Drugs. Ottawa: Health Canada, Canada.
16. EMA (2010) Concept paper on similar biological medicinal products containing recombinant follicle stimulation hormone. A/CHMP/BMWP/94899/2010 London, United Kingdom.
17. Haidar SH, Makhlouf F, Schuirmann DJ, Hyslop T, Davit B, et al. (2008) Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J 10: 450-454.
18. Tothfalusi L, Endrenyi L, Arieta AG (2009) Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet 48: 725-743.
19. Haidar SH, Davit B, Chen ML, Conner D, Lee L, et al. (2008) Bioequivalence approaches for highly variable drugs and drug products. Pharm Res 25: 237-241.
20. Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, et al. (2008) Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J 10: 148-156.